Skip to main content

Table 2 Left Ventricular Function Evaluation by Hemodynamic Measurements and Echocardiograpy

From: Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy

Parameters

Control

(n = 20)

DM

(n = 17)

TSN

(n = 17)

HOE140

(n = 18)

+LV dp/dt max

    

baseline

4449.8 ± 190.2

4458.9 ± 318.7

4462.5 ± 253.5

4430.9 ± 455.8

11 w

4528.2 ± 220.4

3678.6 ± 335.2*

3759.8 ± 372.1*

3699.3 ± 257.2*

12 w

4502.4 ± 254.1

3588.1 ± 454.0*

4180.0 ± 747.9#

3627.3 ± 199.0* ##

-LV dp/dt max

    

baseline

4359.3 ± 397.9

4464.7 ± 469.9

4215.2 ± 681.4

4127.3 ± 579.7

11 w

4265.1 ± 438.2

3561.5 ± 440.6*

3621.5 ± 582.4*

3655.7 ± 492.8*

12 w

4366.7 ± 418.3

3389.9 ± 380.9*

3878.4 ± 526.2* #

3335.7 ± 499.0* ##

LVESV (ml)

    

baseline

0.25 ± 0.06

0.25 ± 0.08

0.25 ± 0.08

0.24 ± 0.08

11 w

0.25 ± 0.05

0.36 ± 0.09*

0.35 ± 0.05*

0.35 ± 0.07*

12 w

0.26 ± 0.06

0.38 ± 0.08*

0.31 ± 0.07* #

0.37 ± 0.07* ##

LVEDV (ml)

    

baseline

1.08 ± 0.07

1.08 ± 0.08

1.07 ± 0.07

1.09 ± 0.07

11 w

1.09 ± 0.08

1.21 ± 0.06*

1.20 ± 0.09*

1.19 ± 0.06*

12 w

1.09 ± 0.07

1.20 ± 0.08*

1.14 ± 0.06* #

1.17 ± 0.08*

LVEF (%)

    

baseline

76.5 ± 5.8

76.8 ± 7.3

76.0 ± 7.5

78.1 ± 7.1

11 w

75.3 ± 5.2

68.2 ± 7.5*

67.4 ± 7.8*

67.1 ± 6.4*

12 w

75.5 ± 4.9

67.9 ± 6.0*

72.1 ± 5.7#

68.5 ± 5.4* ##

  1. LVESV, left ventricular end-systolic volume; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; Values are presented as mean ± SD. * p < 0.05 vs Control, # p < 0.05 vs DM, ## p < 0.05 vs TSN.